Literature DB >> 18306168

Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.

A Ulivieri1, L Lavra, R Dominici, L Giacomelli, E Brunetti, L Sciacca, M Trovato, G Barresi, T Foukakis, L Jia-Jing, C Larsson, A Bartolazzi, S Sciacchitano.   

Abstract

The mechanisms of follicular thyroid carcinoma (FTC) transformation and progression are not well understood. Previously, we detected LOH at 7q21 in all FTCs examined, indicating that loss of genetic material in that region is a common trait in these lesions. To analyse the effects of LOH on gene expression, we performed an analysis of the mRNA expression levels of six different genes, located at 7q21.1-7q21.3. A total of 23 lesions, including eight follicular hyperplasias (FHs), eight follicular adenomas (FAs), two FTCs and five papillary thyroid carcinomas (PTCs) were analysed. The Frizzled-1 (FZD-1) gene, located at 7q21.13, showed the lowest levels of mRNA expression. Down-regulation of FZD-1 expression was also confirmed in an independent series of 69 follicular neoplastic lesions compared to 25 PTCs, analysed by quantitative RT-PCR. In vitro studies showed that FZD-1 expression was also markedly reduced at both protein and mRNA levels in three FTC-derived cell lines (FRO, WRO and FTC-133), while it was normal in the three PTC-derived cell lines (Ca300, Ca301 and K1) examined. We demonstrated that over-expression of FZD-1 in 3 FTC-derived cells decreased invasiveness and proliferation rate, indicating a possible pathogenetic role. In addition, FZD-1 RNA interference in the PTC-derived cell line K1 increased invasiveness. Our data indicated that FZD-1 is involved in growth of follicular tumours and may be considered as a novel marker of this type of tumour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306168     DOI: 10.1002/path.2331

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

Review 1.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

Review 2.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer.

Authors:  Koji Ueno; Hiroshi Hirata; Yuji Hinoda; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

3.  Wingless modulates activator protein-1-mediated tumor invasion.

Authors:  Shiping Zhang; Xiaowei Guo; Honggui Wu; Ying Sun; Xianjue Ma; Jikai Li; Qian Xu; Chenxi Wu; Qiwen Li; Cizhong Jiang; Wenzhe Li; Margaret S Ho; Zhongwei Lv; Lei Xue
Journal:  Oncogene       Date:  2019-01-25       Impact factor: 9.867

4.  The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.

Authors:  Luca Lavra; Cinzia Rinaldo; Alessandra Ulivieri; Emidio Luciani; Paolo Fidanza; Laura Giacomelli; Carlo Bellotti; Alberto Ricci; Maria Trovato; Silvia Soddu; Armando Bartolazzi; Salvatore Sciacchitano
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

5.  Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.

Authors:  Anne-Marie Makhlouf; Zhanna Chitikova; Marc Pusztaszeri; Margaret Berczy; Celine Delucinge-Vivier; Frederic Triponez; Patrick Meyer; Jacques Philippe; Charna Dibner
Journal:  Oncotarget       Date:  2016-07-19

6.  WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.

Authors:  K Brown; P Yang; D Salvador; R Kulikauskas; H Ruohola-Baker; A M Robitaille; A J Chien; R T Moon; V Sherwood
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

7.  Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.

Authors:  Qiang Peng; Lu Wang; Danfeng Zhao; Yulin Lv; Hongzhi Wang; Guang Chen; Jiaqi Wang; Wanhai Xu
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

8.  Identification of Dysregulated Expression of G Protein Coupled Receptors in Endocrine Tumors by Bioinformatics Analysis: Potential Drug Targets?

Authors:  Valentine Suteau; Mathilde Munier; Rym Ben Boubaker; Méline Wery; Daniel Henrion; Patrice Rodien; Claire Briet
Journal:  Cells       Date:  2022-02-17       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.